IRIS
SANTANTONIO, TERESA ANTONIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.741
EU - Europa 15.345
AS - Asia 12.336
SA - Sud America 2.382
Continente sconosciuto - Info sul continente non disponibili 1.375
AF - Africa 194
OC - Oceania 18
Totale 48.391
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.430
CN - Cina 4.803
IE - Irlanda 4.164
SG - Singapore 3.312
UA - Ucraina 3.174
BR - Brasile 1.967
RU - Federazione Russa 1.947
SE - Svezia 1.711
FR - Francia 1.371
HK - Hong Kong 1.245
IT - Italia 1.053
IN - India 975
VN - Vietnam 783
FI - Finlandia 719
TR - Turchia 699
DE - Germania 470
GB - Regno Unito 349
AR - Argentina 159
AT - Austria 147
BD - Bangladesh 107
CA - Canada 104
MX - Messico 102
EC - Ecuador 82
IQ - Iraq 75
EU - Europa 68
ID - Indonesia 64
ZA - Sudafrica 60
CO - Colombia 49
NL - Olanda 44
PK - Pakistan 40
JP - Giappone 38
ES - Italia 33
VE - Venezuela 32
CZ - Repubblica Ceca 31
BE - Belgio 30
SA - Arabia Saudita 29
CL - Cile 26
PL - Polonia 25
UZ - Uzbekistan 25
PY - Paraguay 24
TN - Tunisia 23
MA - Marocco 22
UY - Uruguay 22
EG - Egitto 20
KE - Kenya 20
JM - Giamaica 19
DZ - Algeria 17
DO - Repubblica Dominicana 16
NP - Nepal 15
AU - Australia 14
PE - Perù 14
TT - Trinidad e Tobago 14
AE - Emirati Arabi Uniti 13
CR - Costa Rica 13
IR - Iran 11
OM - Oman 11
RO - Romania 11
HN - Honduras 10
KZ - Kazakistan 10
SY - Repubblica araba siriana 10
TH - Thailandia 10
LT - Lituania 9
SV - El Salvador 9
AZ - Azerbaigian 8
BG - Bulgaria 8
JO - Giordania 8
PR - Porto Rico 8
PT - Portogallo 7
AL - Albania 6
BO - Bolivia 6
MY - Malesia 6
PA - Panama 6
RS - Serbia 6
SN - Senegal 6
CH - Svizzera 5
ET - Etiopia 5
LB - Libano 5
PS - Palestinian Territory 5
EE - Estonia 4
XK - ???statistics.table.value.countryCode.XK??? 4
BB - Barbados 3
BH - Bahrain 3
BY - Bielorussia 3
GR - Grecia 3
HU - Ungheria 3
IL - Israele 3
KG - Kirghizistan 3
KR - Corea 3
KW - Kuwait 3
LV - Lettonia 3
NZ - Nuova Zelanda 3
PH - Filippine 3
AO - Angola 2
CI - Costa d'Avorio 2
CW - ???statistics.table.value.countryCode.CW??? 2
DK - Danimarca 2
GA - Gabon 2
GE - Georgia 2
GH - Ghana 2
KH - Cambogia 2
Totale 47.054
Salva come PNG Salva come JPEG
Città #
Dublin 4.162
San Jose 2.635
Jacksonville 2.225
Singapore 1.398
Dearborn 1.306
Hong Kong 1.236
Chandler 1.219
Nanjing 1.160
Nyköping 877
Ashburn 851
Beijing 707
Wilmington 662
Santa Clara 575
Council Bluffs 528
Princeton 479
Dallas 445
Nanchang 444
Lauterbourg 438
San Mateo 370
Moscow 325
Shenzhen 301
Helsinki 280
Shenyang 258
Ho Chi Minh City 240
Columbus 239
Ann Arbor 222
Tianjin 186
Kunming 178
Hebei 168
Hanoi 148
São Paulo 142
Jiaxing 140
Changsha 139
Hilden 133
Des Moines 128
New York 125
Dong Ket 117
Los Angeles 114
The Dalles 104
Vienna 104
Munich 97
Boardman 95
Hangzhou 95
Bari 90
Stevenage 88
Ningbo 79
Jinan 78
Nuremberg 73
Woodbridge 73
Phoenix 71
Rio de Janeiro 71
Guangzhou 66
Lanzhou 59
Zhengzhou 59
Foggia 54
Shanghai 53
Rome 49
Belo Horizonte 43
London 40
Brasília 38
Changchun 37
Turku 36
San Francisco 35
Taizhou 35
Tokyo 35
Campinas 34
Milan 33
Brooklyn 32
Guayaquil 31
Johannesburg 31
Mexico City 31
Atlanta 30
Orange 30
Boston 29
Frankfurt am Main 29
Chicago 28
Haiphong 28
Orem 28
Philadelphia 27
Pune 27
Brussels 26
Toronto 26
Seattle 25
Da Nang 24
Guarulhos 24
Porto Alegre 24
Redwood City 24
Norwalk 23
Warsaw 23
Baghdad 22
Tashkent 22
Ankara 21
Chennai 21
Curitiba 21
Salvador 21
Auburn Hills 20
Borås 20
Hefei 20
Dhaka 19
Quito 19
Totale 27.950
Salva come PNG Salva come JPEG
Nome #
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. 423
Diagnosi rapida di sepsi: emocoltura e multiplex real time PCR a confronto 421
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 213
Epatite cronica anti-HBe/HBV DNA positiva e mutanti pre-core del virus dell'epatite B 213
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 186
2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE 170
5-year Entecavir in NUC-naïve, field practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC 156
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 152
HCV-related mixed cryoglobulinemia: data from PITER, a nationwide italian HCV cohort study 152
Mucormicosi rino-orbitaria: una patologia da tenere d'occhio 150
Health gains and costs of HCV treatment: a cost effectiveness analysis of two different health policies scenarios simulated in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) real life cohort 149
TERAPIA DELL'EPATITE ACUTA B e C 146
Efficacy of a 24-week course of PEG-Interferon a-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. 144
National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing 144
Clinical and virological features of Hepatitis B and Delta infections in anti-HIV carriers 143
Permanent inhibition of viral replication induced by low dosage of human leukocyte interferon in patients with chronic hepatitis B. 141
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 140
Clinical, epidemiological and virological features of acute hepatitis B in Italy. 139
Nucleios(t)ide analogue discontinuation is not associated with increased rates of HBsAg loss in chronic hepatitis B 139
Chronic viral hepatitis in patients with beta-thalassaemia minor. 135
Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study 134
Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN. 133
A MODEL TO PREDICT SUCCESS FOLLOWING PEG-INTERFERON AND RIBAVIRIN THERAPY FOR PATIENTS WITH HCV-1 INFECTION 133
Natural course of acute hepatitis C: a long-term prospective study 132
5-YEAR ENTECAVIR TREATMENT IN NUC-NAIVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS 131
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. 131
HCV infection is a risk factor for gallstone disease in liver cirrhosis: An Italian epidemiological survey 131
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 131
Peculiar clinical presentation of COVID-19 and predictors of mortality in the elderly: A multicentre retrospective cohort study 131
The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug? 130
Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features 130
Clinical value of HIV p24 Ag in cerebrospinal fluid of symptomatic or asymptomatic HIV-infected patients 130
Real life clinical outcomes in DAA-treated and untreated patients with HCV advanced liver disease. Interim one year data from the ongoing PITER cohort 130
Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic epatiti B 129
Possible mechanisms involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. 128
Real Time PCR and Culture-Based Virus Isolation Test in Clinically Recovered Patients: Is the Subject Still Infectious for SARS-CoV2? 128
Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. 127
Acute Hepatitis C in Haemodialysis patients: natural course and response to IFNα-monotherapy 127
Flares during long-term entecavir therapy in chronic hepatitis B 126
Tocilizumab and corticosteroids for covid-19 treatment in elderly patients. Journal of Gerontology and Geriatrics 126
Feasibility of vaccination in preventing secondary cases of hepatitis A virus infection. 125
Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant Chronic Hepatitis B 125
HCV-RELATED MIXED CRYOGLOBULINEMIA: DATA FROM PITER, A NATIONWIDE ITALIAN HCV COHORT STUDY 125
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. 125
Non-A,non-B hepatitis virus. 124
Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. 124
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. 124
Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. 124
Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. 123
A proposito di epatite B. News da EASL 2008. 123
OptiB Italian multicenter prospective study on tenofovir in suboptimal responders to ADV or ADV/LAM treatment: 96 weeks results on efficacy and tolerance. 123
Correlation between knowledge on transmission and prevention of HIV/STI and proficiency in condom use among male migrants from Africa and Middle East evaluated by a Condom Use Skills score using a wooden penile model. 123
Efficacy and Safety of Remdesivir over Two Waves of the Sars-CoV-2 Pandemic 123
EFFICACY AND SAFETY OF LONG-TERM THERAPY WITH ENTECAVIR (ETV) OR TENOFOVIR (TDF) IN PATIENTS WITH HBV-RELATED CIRRHOSIS 122
Diagnosi sierologica dell'epatite acuta da virus A. Messa a punto e valutazione di tre metodiche per la determinazione delle IgM specifiche anti-HAV 122
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice: high efficacy and favourable safety profile over 3 years of treatment 122
Four years of tenofovir monotherapy for NUC naive field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 122
Comparison between HCV RNA and E1/E2 antibodies in patients on IFN treatment 122
preliminary Data From the Study of Coagulative Profile of HIV infected Individuals suggest a role for point mutations in the Gene in protein S deficiency in Individuals undergoing Higly Antiretroviral therapy 122
LE VARIANTI GENOMICHE DELLA REGIONE PRE-CORE DEL VIRUS DELL'EPATITE B: ASPETTI PATOGENETICI E CLINICI 121
Selection of a secretion incompetent mutant in the serum of a patient with severe hepatitis B 120
Sustained virological response to interferon-alfa is associated with improved outcome in HCV-related cirrhosis: a retrospective study. 120
Lack of HBV and HDV replicative activity in HBsAg-positive intravenous drug addicts with immune deficiency due to HIV. 120
IFN impact on liver disease progression in HBeAg negative chronic hepatitis B (CHB): a long-term Italian multicenter AISF study 120
Tipizzazione fenotipica di Klebsiella Pneumoniae MDR mediante MALDI-TOFS MS in isolati clinici della Rianimazione A.O.U. OO. RR. Foggia 120
Patients with HDV infection and advanced fibrosis/cirrhosis present a high but predictable risk of developing hepatocellular carcinoma 120
.Long-term lamivudine treatment in patients with HBeAg negative chronic hepatitis B: how long? 119
Treatment prioritization according to the EASL HCV CPG 2015: a real-life evaluation on the PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort 119
Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. 118
Estimating minimum adult HIV prevalence: a cross-sectional study to assess the characteristics of people living with HIV in Italy. 118
Chronic hepatitis B: Advances in treatment. 118
Interim analysis of the Italian Master-Entas cohort study: entecavir effectiveness in field practice for chronic hepatitis B 117
Variation of pre-C and pre-S sequences during Interferon therapy 117
Long-term response to interferon therapy in hepatitis B virus (HBV) pre-C mutants associated chronic hepatitis 117
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study 117
Lamivudine/Interferon combination therapy in anti-HBe positive chronic hepatitis B patients; a controlled pilot study. 116
Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B. 116
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin 116
Gly145 to Arg substitution in HBs antigen of liver transplant patients receiving polyclonal hepatitis B immune globulin 116
Selection of HCV-1 patients with chronic hepatitis who might benefit from current standard of therapy with peg-interferon and ribavirin 116
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? 116
Determinazione immunoenzimatica delle IgA specifiche anti-HAV nella diagnosi sierologica dell'epatite A 115
A multicenter Italian study of rescue Adefovir Dipivoxil therapy in lamivudine resistant patients: a 2-year analysis of 604 patients 115
PREDICTION OF HBeAg SEROCONVERSION IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH ENTECAVIR USING ALT AND PLATELET COUNT: RESULTS FROM A LARGE EUROPEAN MULTI-CENTER STUDY 115
Comparison Of Markers Of Bone Turnover Demonstrates Less Changes In CHB Patients Receiving Tenofovir Alfenamide (TAF) Compared with Tenofovir disoproxil fumarate (TDF) 115
Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation 114
Virologic and clinical expression of reciprocal inhibitory effect of Hepatitis B, C, and Delta viruses in patients with chronic hepatitis 114
Effects of HIV superinfection on HBV replication in a chronic HBsAg carrier with liver disease. 113
Acute hepatitis C: current status and remaining challenges. 113
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues 113
SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients 113
Analisi di costo-efficacia del trattamento dell’epatite cronica B con analoghi nucleos(t)idici nella pratica clinica 113
RIELISA: a new principle for the simultaneous detection of total and IgM antibodies. Application to hepatitis diagnosis 113
Clinical and virological features of HBV and HDV chronic hepatitis in subjects with HIV infection 113
ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT 113
Male gender, genotype 3, previous alcohol use, increased BMI, and diabetes are factors independently correlated to advanced HCV chronic liver disease in Italy: data from PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort study 113
Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon. 112
Dendritic Cell Maturation in HCV Infection: Altered Regulation of MHC Class I Antigen Processing-Presenting Machinery 112
Selection during interferon treatment for a pre-C stop codon mutation in a hepatitis B virus variant despite the simultaneous presence of a pre-C initiation codon mutation 112
New principle for the simultaneous detection of total and immunoglobulin M antibodies applied to the measurement of antibody to hepatitis B core antigen. 111
Totale 13.346
Salva come PNG Salva come JPEG
Categoria #
all - tutte 249.558
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 249.558
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.170 0 0 0 70 341 129 69 234 310 297 102 618
2022/20238.169 950 196 274 370 335 603 32 474 4.613 105 122 95
2023/20241.203 171 61 364 40 78 174 92 60 8 18 11 126
2024/20256.213 326 39 67 131 73 781 1.011 344 1.812 418 589 622
2025/202611.429 633 657 1.643 2.299 289 376 2.485 989 913 682 188 275
2026/20271.866 184 910 769 3 0 0 0 0 0 0 0 0
Totale 48.391